---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-011155"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:23:12.619192+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Voyager delays SOD1 ALS IND filing; switches payload after NHP data; cash runway to mid-2027

## Summary
- VY9323 IND/CTA filing no longer expected mid-2025 due to need for alternate payload after 3-month NHP data.
- Capsid unchanged; decision based on achieving desired product profile for SOD1 ALS gene therapy.
- Other programs unaffected: Neurocrine GBA1 and Friedreich’s ataxia IND filings still on track for 2025.
- Tau silencing program VY1706 IND expected in 2026; preclinical activity levels achieved.
- Cash and equivalents plus collaboration reimbursements fund operations into mid-2027.

## SEC filing metadata
- accession: 0001104659-25-011155
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465925011155/0001104659-25-011155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465925011155/tm256087d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-011155
- JSON: https://secwatch.observer/filing/0001104659-25-011155.json
- Plain text: https://secwatch.observer/filing/0001104659-25-011155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.